文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

台湾多重耐药结核病的治疗结局:应对失访问题

Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up.
PubMed 文献 · Clin Infect Dis · 2018-01-01

台湾MDR-TB Consortium(TMTC)于2007年5月成立,本研究分析其前5年入组的692例耐多药结核病患者。采用免费综合照护、4-5药联合方案、疗程18-24个月、个案管理与直接观察治疗,30个月时570例(82.4%)治疗成功,84例(12.1%)死亡,18例(2.6%)治疗失败,20例(2.9%)失访。年龄≥65岁、癌症、慢性肾病与死亡显著相关,氟喹诺酮类耐药与治疗失败显著相关。

要点

  • TMTC前5年入组692例MDR-TB患者,570例(82.4%)治疗成功,20例(2.9%)失访。
  • 年龄≥65岁(aOR 6.78)、癌症(aOR 11.82)、慢性肾病(aOR 3.62)与死亡显著相关。
  • 氟喹诺酮类耐药(aOR 10.89)与治疗失败显著相关。

核心结论

  • TMTC在公共卫生主管部门与临床团队紧密合作下运行,是管理MDR-TB的高度有效照护模式。

研究设计与样本

  • 分析台湾MDR-TB Consortium(TMTC)成立后前5年入组的692例耐多药结核病患者,采用国际推荐结局定义在30个月时评估治疗结局。

主要发现

  • 692例中570例(82.4%)治疗成功,84例(12.1%)死亡,18例(2.6%)治疗失败,20例(2.9%)失访。
  • 年龄≥65岁(aOR 6.78,95%CI 3.14-14.63)、癌症(aOR 11.82,95%CI 5.55-25.18)、慢性肾病(aOR 3.62,95%CI 1.70-7.71)与死亡显著相关。
  • 氟喹诺酮类耐药(aOR 10.89,95%CI 3.97-29.88)与治疗失败显著相关。

关键数值与推荐

  • 治疗方案由4-5种药物组成,疗程18-24个月。
  • 为每例患者分配个案管理者和直接观察治疗提供者。
  • 提供免费综合照护,患者通常初始住院1个月。
  • 提供心理社会支持以应对情绪压力和污名化,并提供经济支持以避免患者及其家庭面临经济困难。

临床怎么用

  • TMTC模式包括免费综合照护、4-5药联合方案、18-24个月疗程、个案管理与直接观察治疗、心理社会及经济支持,在公共卫生主管部门与临床团队紧密合作下运行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The proportion of treatment success among patients with multidrug-resistant tuberculosis (MDR-TB) enrolled between 1992 and 1996 was 51.2%, and that among patients enrolled between 2000 and April 2007 was 61%. To address the challenge of MDR-TB, the Taiwan MDR-TB Consortium (TMTC) was established in May 2007. To assess the performance of the TMTC, we analyzed the data of patients enrolled in its first 5 years. METHODS: Comprehensive care was provided at no cost to patients, who were usually hospitalized for 1 month initially. Treatment regimens consisted of 4-5 drugs and the duration of treatment was 18-24 months. A case manager and a directly observed therapy provider were assigned to each patient. Psychosocial support was provided to address emotional stress and stigma. Financial support was offered to avoid the financial hardship faced by patients and their families. We assessed treatment outcomes at 30 months using internationally recommended outcome definitions. RESULTS: Of the 692 MDR-TB patients, 570 (82.4%) were successfully treated, 84 (12.1%) died, 18 (2.6%) had treatment failure, and 20 (2.9%) were lost to follow-up. Age ≥65 years (adjusted odds ratio [aOR], 6.78 [95% confidence interval {CI}, 3.14-14.63]), cancer (aOR, 11.82 [95% CI, 5.55-25.18]), and chronic kidney disease (aOR, 3.62 [95% CI, 1.70-7.71]) were significantly associated with death. Resistance to fluoroquinolone (aOR, 10.89 [95% CI, 3.97-29.88]) was significantly associated with treatment failure. CONCLUSIONS: The TMTC, which operates under a strong collaboration between the public health authority and clinical teams, has been a highly effective model of care in the management of MDR-TB.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yu MC, Chiang CY, Lee JJ, et al. Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up. Clin Infect Dis. 2018. PMID: 29394358. doi:10.1093/cid/ciy066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。